Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Inflation Reduction Act Research Series: Medicare Enrollees’ Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program

Publication Date
Aug 29, 2023

The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that have high total spending and are high expenditure, single source drugs without generic or biosimilar competition. Negotiations with participating manufacturers for the first group of selected drugs for initial price applicability year 2026 begin in 2023, with negotiated maximum fair prices going into effect in 2026. This Fact Sheet provides descriptive information on the use and out-of-pocket spending in calendar year 2022 for each of the drugs selected for negotiation for initial price applicability year 2026 under the Medicare Drug Price Negotiation Program. We examined the use of these 10 drugs and out-of-pocket spending on them for Medicare Part D enrollees overall, by low-income subsidy (LIS) status, by demographic characteristics, and by state of residence.

Related Products:

*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Bisma Sayed, (202)240-3884, Content will be updated pending the outcome of the Section 508 review.

Product Type
Fact Sheet
Older Adults | Racial & Ethnic Groups | Medicare Beneficiaries
Location- & Geography-Based Data
National Data | State Data
Medicare Part D